On May 18, 2016 Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported it will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the Trials in Progress Session of the 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held in Chicago from June 3-7 (Filing, 6-K, Trillium Therapeutics, MAY 18, 2016, View Source [SID:1234512630]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of Trillium’s ASCO (Free ASCO Whitepaper) presentation are as follows:

Presentation Type: Poster
Abstract #: TPS7585
Title: A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory hematologic malignancies
Presenter: Stephen Maxted Ansell, M.D., Ph.D., Division of Hematology, Mayo Clinic
Track: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia
Time/Location: Monday, June 6, 8-11:30 a.m. in Hall A, Poster Board #134b